Xenikos is developing a novel therapy that enables patients suffering serious immune diseases, or rejection after transplantation, to reset their immune system quickly and efficiently. Xenikos’ mission is to develop new, innovative immunotherapy medicines to help restore patients’ health and save lives.
Latest news
8 september 2021
19 juli 2021
Introducing T-Guard®
T-Guard® is a medicine currently under development that safely and swiftly ‘resets’ the body’s immune system. It shows potential in the effective treatment of certain life-threatening immune conditions, such as transplant-related rejection, acute graft-versus-host disease (aGVHD), solid-organ rejection and several severe autoimmune diseases.
Our investors
